The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data are available to support a role for single nucleotide polymorphisms or other investigational markers in early detection.
Several commercially available blood and urine tests have been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.
Current opinion in urology. 2016 Jun 03 [Epub ahead of print]
Stacy Loeb, Hans Lilja, Andrew Vickers
aDepartment of Urology bDepartment of Population Health, New York University cDepartment of Laboratory Medicine dDepartment of Surgery eDepartment of Medicine fDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA gNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK hDepartment of Translational Medicine, Lund University, Malmö, Sweden.